Provided by Tiger Trade Technology Pte. Ltd.

BioAtla, Inc.

1.74
-1.4050-44.75%
Post-market: 1.760.0250+1.44%19:59 EDT
Volume:1.03M
Turnover:1.82M
Market Cap:2.89M
PE:-0.07
High:2.10
Open:1.58
Low:1.51
Close:3.14
52wk High:71.50
52wk Low:1.51
Shares:1.67M
Float Shares:1.37M
Volume Ratio:8.75
T/O Rate:75.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-25.0700
EPS(LYR):-50.6621
ROE:-813.88%
ROA:-105.86%
PB:-0.08
PE(LYR):-0.03

Loading ...

BioAtla Faces Nasdaq Delisting, Plans OTC Market Move

TIPRANKS
·
Aug 28

BioAtla Faces NASDAQ Delisting After Listing Council Affirms Suspension Decision

Reuters
·
Aug 28

BioAtla Q2 FY26 Swings to Net Income of $452,000; Revenue Rises to $6.5 Million

Reuters
·
Aug 14

Bioatla Holds Annual Shareholder Meeting Via Webcast

Reuters
·
Jul 17

Context Therapeutics enters license agreement amendment with BioAtla

TIPRANKS
·
May 18

Context Therapeutics pays USD 6.5 million to buy out CT-202 milestones, royalties

Reuters
·
May 18

Context Therapeutics Enters Into License Agreement Amendment With Bioatla for Ct-202

THOMSON REUTERS
·
May 18

Context Therapeutics - Announces Buyout of Ct-202 Future Milestones and Royalties

THOMSON REUTERS
·
May 18

Context Therapeutics: Amendment Removes All Future Milestone and Royalty Obligations Owed by Company for Ct-202

THOMSON REUTERS
·
May 18

Context Therapeutics - to Pay $4.5 Mln Upfront and $2.0 Mln by Aug 1, 2026 for Ct-202 License

THOMSON REUTERS
·
May 18

Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202

GlobeNewswire
·
May 18

BioAtla Q1 FY26 net loss narrows 58.63% to $6.34 million

Reuters
·
May 16

BioAtla trading halted, news pending

TIPRANKS
·
Apr 03

BioAtla Announces 1-for-50 Reverse Stock Split Merger

TIPRANKS
·
Apr 03

BioAtla completes merger of BA Merger Sub into company effective April 6, 2026

Reuters
·
Apr 03

BioAtla Begins Strategic Review Following 2025 Results

TIPRANKS
·
Apr 01

BioAtla Q4 EPS $(0.16) Beats $(0.30) Estimate, Sales $2.000M Beat $700.000K Estimate

Benzinga Earnings
·
Apr 01

BioAtla to execute 50-for-1 share consolidation April 6

Reuters
·
Apr 01

BioAtla FY25 net loss narrows to $60 million; R&D expenses fall to $44 million

Reuters
·
Apr 01

Press Release: BioAtla Announces Share Consolidation

Dow Jones
·
Apr 01